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Background: Differently from HIV-1, HIV-2 disease progression usually takes decades without antiretroviral therapy
and the majority of HIV-2 infected individuals survive as elite controllers with normal CD4+ T cell counts and low or
undetectable plasma viral load. Neutralizing antibodies (Nabs) are thought to play a central role in HIV-2 evolution
and pathogenesis. However, the dynamic of the Nab response and resulting HIV-2 escape during acute infection
and their impact in HIV-2 evolution and disease progression remain largely unknown. Our objective was to
characterize the Nab response and the molecular and phenotypic evolution of HIV-2 in association with Nab escape
in the first years of infection in two children infected at birth.
Results: CD4+ T cells decreased from about 50% to below 30% in both children in the first five years of infection
and the infecting R5 viruses were replaced by X4 viruses within the same period. With antiretroviral therapy, viral
load in child 1 decreased to undetectable levels and CD4+ T cells recovered to normal levels, which have been
sustained at least until the age of 12. In contrast, viral load increased in child 2 and she progressed to AIDS and
death at age 9. Beginning in the first year of life, child 1 raised high titers of antibodies that neutralized primary R5
isolates more effectively than X4 isolates, both autologous and heterologous. Child 2 raised a weak X4-specific Nab
response that decreased sharply as disease progressed. Rate of evolution, nucleotide and amino acid diversity, and
positive selection, were significantly higher in the envelope of child 1 compared to child 2. Rates of R5-to-X4
tropism switch, of V1 and V3 sequence diversification, and of convergence of V3 to a β-hairpin structure were
related with rate of escape from the neutralizing antibodies.
Conclusion: Our data suggests that the molecular and phenotypic evolution of the human immunodeficiency virus
type 2 envelope are related with the dynamics of the neutralizing antibody response providing further support for
a model in which Nabs play an important role in HIV-2 pathogenesis.
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Infection with human immunodeficiency virus type 2
(HIV-2) affects 1-2 million individuals mostly living in
West Africa, India and Europe [1,2]. Eight different
HIV-2 groups named A through H have been reported
but only viruses from groups A and B are known to
cause human epidemics [3,4]. Among those, viruses
from group A are responsible for the vast majority of
HIV-2 infections worldwide.
Even though HIV-1 and HIV-2 are closely related vi-
ruses and share a high degree of similarity, infections by
these viruses lead to very different immunological and
clinical outcomes. HIV-2 infection eventually leads to
CD4 depletion, AIDS and death [5-7]. However, differ-
ently from HIV-1, HIV-2 disease progression usually
takes decades without antiretroviral therapy and the ma-
jority of HIV-2 infected individuals survive as elite con-
trollers with normal CD4+ T cell counts and low or
undetectable plasma viral load [8-16]. Understanding of
the factors involved in the effective control of viral repli-
cation and disease progression in HIV-2 infected indi-
viduals might prove crucial to devise the best strategy to
prevent and treat HIV-1.
Enhanced immune control could explain the mild out-
come of most HIV-2 infections. Unlike HIV-1 infected
patients, most HIV-2 patients in chronic stage produce
potent and broad neutralizing antibodies [17-21]. Recent
evidence has shown that the viruses isolated from HIV-2
infected patients with advanced disease are characterized
by increased resistance to entry inhibitors, including the
CCR5-antagonist maraviroc [22] and neutralizing anti-
bodies [23], and by a remarkably high evolutionary rate
[24,25]. These results suggest that neutralizing anti-
bodies play a central role in HIV-2 evolution and patho-
genesis. However, in contrast to HIV-1, still nothing is
known about the neutralizing antibody response and the
molecular and phenotypic features of HIV-2 in acute/
early infection because HIV-2 patients are usually diag-
nosed many years after seroconversion.
Most neutralizing epitopes in the HIV-2 envelope
glycoprotein complex are located in the surface gp125
glycoprotein. They have been identified in V1, V2, V3,
V4 and C5 regions, and in the CD4-binding site
[19,21,23,26-29]. These epitopes are well exposed in the
envelope complex of CCR5-using isolates that are usu-
ally highly sensitive to antibody neutralization [21,27].
However, X4 isolates that emerge in late stage infection
in some HIV-2 patients when C2V3C3-specific neutral-
izing antibodies wane are highly resistant to antibody
neutralization [23]. The V3 loop sequence, size and con-
formation of the X4 isolates are markedly different from
those of R5-neutralization sensitive isolates supporting a
direct role of this region in escape from neutralization
and a direct role of the neutralizing antibodies inshaping the evolution of V3 in progressive HIV-2 infec-
tion. The neutralizing domains expressed in the enve-
lope glycoproteins in acute/early infection and the role
of the neutralizing antibodies and neutralization escape
in shaping the evolution of the HIV-2 envelope in this
period remains to be determined.
Perinatal transmission of HIV-2 is a rare event that in
Europe has only been documented in Portugal [30-34]
and France [35]. Vertical transmission cases constitute a
unique opportunity to study the phenotypic and molecu-
lar evolution of HIV-2 Env in acute and early infection
as well as the role of Nabs in this process. Our objective
was to characterize the evolution of the Nab response in
two children infected with HIV-2 at birth in association
with the molecular and phenotypic evolution of the
virus. We show that broad and potent Nabs can be elic-
ited very early after infection and that HIV-2 Env evolves
at a very high rate in the first years of infection, this rate
being directly associated to the potency of the Nab re-
sponse. R5-to-X4 tropism change, increased diversity in
V1 and V3, and selected changes in V3 conformation
were associated with escape from antibody neutralization.
The data suggests that the rapid molecular and phenotypic
evolution of the HIV-2 envelope in the first years of infec-
tion is related with the selective pressure imposed by the
neutralizing antibodies.
Results
Clinical and virological progression is very fast in the first
years of infection
Child 1 infection was diagnosed with HIV-2 infection
by PCR and virus isolation in the first month of life in
1998. To confirm the vertical transmission event and
characterize the initial infecting virus population, 8 clonal
full-length env gene sequences were obtained from sam-
ples collected in 1998, 2000 and 2003 (in total 24 env se-
quences) and from his mother (mother 1-PTHCC20) in
2000 and 2003 (16 env gene sequences). We were unable
to obtain 1998 samples from the mother.
Child 2 infection was diagnosed in 1992 at day 39 after
birth by PCR and virus isolation, and vertical transmis-
sion was confirmed by phylogenetic analysis of partial
env sequences from the mother and the child [31,32].
Eight new clonal full-length env sequences were ob-
tained from samples collected in 1992, 1997 and 2001
(in total 24 env sequences).
Phylogenetic analysis showed that all sequences belonged
to HIV-2 group A and that mother and child sequences
shared a common ancestor, being more closely related
to each other than to any other sequences, which con-
firms the two vertical transmission events (Figure 1).
The sequences showed patient-specific clustering, forming
sub-clusters corresponding to each year of infection.
The sequences from the first sample from both children
Figure 1 Evolutionary relationships between mother and child env sequences. A maximum likelihood phylogenetic tree was constructed
using alignments of clonal env sequences obtained from the children in successive years and from their mothers with reference sequences from
HIV-2 groups A, B and G. The bootstrap values supporting the internal branches are shown as follows: * bootstrap >70, ** bootstrap >90. The
scale bar represents evolutionary distance in number of substitutions per site. Sequences from child 1 (PTHDECT) are represented by red ircles,
with each year of sample collection in orange (1998), red (2000) and dark red (2003); sequences from mother 1 (PTHCC20) are represented by
green circles, with each of sample collection in light green (2000) and dark green (2003); sequences from child 2 (PTHDESC) are represented by
blue squares with each year of sample collection in light blue (1992), blue (1997) and dark blue (2001); sequence from mother 2 has been
published before [32] and is represented by a pink square. The tropism of the viruses is indicated to the right of each cluster.
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supported by high bootstrap values indicating that one or
two virus variants were transmitted from the mothers to
the children (Figure 1).
Child 1 was born with normal CD4 percentage (47%)
which was sustained until age 3 without ART. The initial
infecting virus was CCR5-tropic according to V3 loop se-
quence analysis of env gene clones obtained in 1998 and
to phenotypic analysis of virus isolated in 2000 (Table 1
and Figure 1). At age 5, in 2003, CD4 levels decreased to
27%, plasma viral load increased significantly and the virus
changed to CXCR4-tropic as determined by phenotypic
analysis [22]. Antiretroviral therapy (ART) was initiated at
that time leading to a decrease in viral load to undetect-
able levels and to an increase in CD4+ T cells to normal
levels. Presently, this child is clinically and immunologic-
ally stable and remains asymptomatic.Child 2 was born with encephalopathy (CDC clinical
stage C1) but with normal CD4+ T cell percentage (52%)
and undetectable viral load [31,32] (Table 1). The initial
infecting virus was CCR5-tropic, as determined by our
V3 loop sequence analysis, but induced syncytia forma-
tion in peripheral blood mononuclear cells [31,32].
At age 5, CD4 percentage decreased to 25% and the
virus changed to CXCR4-tropic, as determined by V3
loop sequence analysis. AZT therapy (1992 up to 1997)
and AZT + 3TC therapy (in 2001) did not prevent in-
crease in viral load and further CD4+ T cell decline and
the child died of AIDS at age 9.
Potent neutralizing antibodies are produced since the
first year of infection especially against R5 isolates
Plasma samples were available from day 27 of birth until
the age of 12 for child 1, and from age 5 until age 9
Table 1 Virological and immunological characterization of the patients
Patient Sampling year Age (Years) Viral load (RNA
copies/ml plasma)
Viral tropisma Number of CD4+
T cells/μl (%)
Drug regimen Disease stageb
Child 1 1998 0.11c <200 R5 5342 (47) - N
1999 1 <200 nd 2992 (50) - N
2000 2 1355 R5 2919 (43) - A1
2001 3 nd nd 3253 (51) - A1
2003 5 20968 X4 595 (27) d4T + 3TC + LPV/RTV B2
2006 8 <200 nd 1895 (55) d4T + 3TC + LPV/RTV A1
2010 12 <40 nd 1878 (54) 3TC + ABC + LPV/RTV A1
Child 2 1992 0.07d <200 R5e 1670 (52) AZT C1
1997 5 <200 X4 1050 (25) AZT C1
1999 7 13883 nd 127 (15) AZT C1
2001 9 1250 X4 44 (5) AZT + 3TC C3 (death)
aAs determined phenotypically in TZMbl cells [22] or genotypically based on V3 loop sequence patterns [36]; bAccording to the CDC revised classification system
for HIV infection in children; cFirst blood collection was at day 39 after birth; dFirst blood collection was at day 27 after birth; eIsolate obtained at birth was
syncytium inducing as determined in PBMCs and several cell lines [32]; d4T–stavudine, 3TC–lamivudine, LPV–lopinavir, RTV–ritonavir, ABC–abacavir,
AZT–zidovudine; nd–not determined.
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was tested against autologous virus isolates obtained at
age 2 (R5 isolate, CT00) and at age 5 (X4 isolate, CT03)
for child 1, and at age 9 for child 2 (X4 isolate, SC01)
(Figure 2). For child 1, the most notorious findings were
the steep increase in Nab titers against the initial R5 iso-
late (CT00) during the first 5 years of infection and the
high Nab titers still present at age 12 against this isolate.Figure 2 Evolution of the autologous neutralizing antibody response
activity present in patients plasma was analyzed against their primary virus
from child 1 from years 1998, 1999, 2000, 2001, 2003, 2006 and 2010 were
circles] and 2003 [CT03 (X4 tropism)–green circles] and plasma from child 2
autologous virus from 2001 [SC01 (X4 tropism)–blue diamonds]. Nab titers
each serum/virus. Open symbols signal the neutralization of the contempo
virus present at that time of infection and dotted lines represent neutraliza
to compare IC50 values obtained for CT00 (R5) and CT03 (X4) isolates. ***PHowever, Nabs produced during the initial infection
period and during later periods were significantly less
potent against the X4 isolate that emerged in 2003 at
age 5 (CT03) [median (range) of reciprocal log10 IC50
neutralization titers against CT00 and CT03 were 4.6
(3.7-5.4) and 4.1 (3.2-4.4), respectively, P = 0.0472,
Mann–Whitney test]. This difference in susceptibility to
neutralization of the two isolates was particularly evidentin the children over the course of infection. The neutralizing
isolates using a luciferase reporter gene assay in TZM-bl cells; plasma
tested against autologous viruses from 2000 [CT00 (R5 tropism)–pink
from years 1997, 1998, 1999 and 2001 were tested against
are presented as median (symbols) and interquartile range (shades) for
raneous isolate. In child 1, straight lines represent neutralization of the
tion of virus not present at that time of infection. The F test was used
= 0.0008, ****P < 0.0001.
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child. The close associations between rates of Nab es-
cape and R5-to-X4 phenotypic switching suggests that
phenotype transition in this infant is directly related with
the Nab pressure.
Notably, child 1 also produced neutralizing antibodies
that potently neutralized several heterologous primary
HIV-2 isolates. Again, the heterologous Nabs were sig-
nificantly more effective against R5 strains than against
X4 strains [median (range) of reciprocal log10 IC50
neutralization titers against R5 and X4 isolates were 3.5
(1.6-4.0) and 2.5 (1.6-4.0), respectively, P = 0.0041]
(Figure 3).
In child 2 we could only analyse the evolution of Nab
response against the autologous X4-isolate (SC01) from
age 5 onwards. Comparing Nab response at age 5 in
both patients (the only age-matched data point), we
found that it was significantly weaker in child 2 than
in child 1 [median (range) of reciprocal log10 IC50
neutralization titer of child 2 against SC01 was 3.5 (3.4-
3.6), and those of child 1 against autologous CT00 andFigure 3 Neutralizing antibody response against heterologous prima
the reciprocal log-transformed IC50 value of each plasma sample from chil
with respective tropism (top) is shown. The reciprocal log10 IC50 value is co
was still detected with the highest plasma dilution tested (1/5120). The ligh
above 50% with the lowest plasma dilution tested (1/40). n.d.–not done (d
standard deviation of the reciprocal log10 IC50 values obtained against R5
compare the median log10 reciprocal IC50 values.CT03 isolates were 5.3 (5.0-5.5) and 4.2 (4.0-4.4), re-
spectively, P < 0.001] (Figure 2). Moreover, in contrast
to child 1, Nab titer decreased steadily with infection
time as viral load increased and disease progressed to
AIDS and death at age 9 (Figure 2 and Table 1). Consid-
ering all time points together, average Nab titers were
lower than those of child 1 against the age-matched X4
isolate CT03 [median (range) of reciprocal log10 IC50
neutralization titer against isolates SC01 and CT03 were
3.3 (3.0-3.5) and 4.1 (3.2-4.4), respectively, P = 0.057]
and against the R5 isolate CT00 [median (range) of re-
ciprocal log10 IC50 neutralization titer against isolates
SC01 and CT00 were 3.3 (3.0-3.5) and 4.6 (3.7-5.4), re-
spectively, P = 0.0106].
HIV-negative plasmas failed to neutralize HIV-2
strains and HIV-2 plasmas failed to neutralize HIV-
1SG3.1 or viruses pseudotyped with VSV envelope indi-
cating the absence of nonspecific inhibitory activities in
these samples.
Overall, the results obtained with child 1 demonstrate
that potent neutralizing antibodies (autologous andry isolates in child 1 over the course of infection. A) A heat map of
d 1 (left) against a panel of five heterologous primary virus isolates
lour-coded. The darkest colour indicates that neutralization above 50%
test colour indicates that there was no detectable neutralization
ue to lack of plasma); B) Dot-plot graphic showing the mean and
and X4 isolates indicated in A. Mann–Whitney U test was used to
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vertical infection. Nabs are highly effective against the
transmitted R5 isolates but seem to rapidly select for X4
isolates that escape neutralization. In the absence of ef-
fective antiretroviral therapy, as was the case of child 2,
increased replication of the Nab-resistant X4 isolates
likely contributed to rapid CD4+ T cell depletion and
progression to AIDS.
HIV-2 Env evolution in acute/early and late infection
At birth, nucleotide diversity in child 1 was twice that of
child 2 in env and five times in C2V3C3 region (Table 2).
At age 5, nucleotide diversity increased 2-fold in env and
C2V3C3 in child 1 while in child 2 it only increased in
C2V3C3 (2-fold) leading to an even higher difference in
env and C3V3C3 diversity (3-and 6-fold, respectively).
Interestingly, in child 2, diversity increased significantly
from age 5 onward, both in env (4-fold when compared
to diversity at age 5) and C2V3C3 (11-fold) exceeding
that of child 1 at age 5. However, in contrast to the first
years of infection, most substitutions occurring in this
period were of a synonymous nature as indicated by the
sharp decrease in the ω value both in env and C2V3C3.
The evolutionary rate of env was significantly higher in
child 1 than in child 2 (0.0141 vs 0.0073 substitutions/site/
year, posterior probability (PP) value <5%) (Table 2). When
focusing on the C2V3C3 region, the evolutionary rates
were not significantly different (0.0142 vs 0.0105 substitu-
tions/site/year, PP=20%). There was a trend towards posi-
tive selection in child 1 (non-synonymous rate: env, 0.0143
and V3, 0.0152; synonymous rate: env, 0.0137 and V3,
0.0124 substitutions/site/year) and purifying selection in
child 2 (non-synonymous rate: env, 0.0069 and V3, 0.0092;
synonymous rate: env, 0.0082 and V3, 0.0132 substitu-
tions/site/year) in both env and V3.
We also analysed the evolution of amino acid diversity,
as determined by the sum of Shannon’s entropy, in vari-
able regions of gp125 which contains most of the neu-
tralizing domains [19,21,26,27]. At birth, amino acid
diversity was higher in child 1 than in child 2 (Table 3).Table 2 Nucleotide diversity and divergence rates in the env
Patient Sampling
year
Age
(years)
ωa Nucleotide
env C2V3C3 env
Child 1 1998 0.11 0.96 1.52 0.013 (0.0061)
2000 2 0.88 5.78 0.027 (0.0047)
2003 5 0.65 0.50 0.027 (0.0057)
Child 2 1992 0.07 1.15 0.38 0.007 (0.0022)
1997 5 0.99 2.60 0.008 (0.0025)
2001 9 0.66 0.62 0.035 (0.0122)
aRatio of nonsynonymous to synonymous substitution rates; bWithin-patient geneti
tree distances over all the sequences obtained for each patient at each time point;At age 5, amino acid diversity increased significantly
only in V1 and V3 in both patients, this being much
more pronounced in child 1. In child 2, from age 5 to
age 9 (death), amino acid diversity increased in V1 (9.3-
fold), V3 (2.1-fold) and V4 (1.6-fold), though never
reaching the level of diversity observed in child 1 at
age 5. Amino acid changes observed after the first year
in V1 and V3 are shown in Figure 4. In V1 there was no
clear pattern of change except for the 2-4 amino acids
deletion detected at year 5 in both patients. This dele-
tion was maintained along the full course of infection in
child 2. In child 1, three mutations occurring at age 3
were fixed (were kept in year 5) and 4 mutations re-
versed back to the original residue suggesting that these
changes affected viral fitness; in child 2, ten mutations
were fixed over the course of infection and there were
no reversions suggesting that the mutations did not re-
duce the fitness of the virus or that compensatory muta-
tions occurred in other regions. Three of the fixed
mutations in child 2 were located in a previously de-
scribed neutralizing epitope [26]. Likewise, in child 1
two mutations of a potentially disruptive nature emerged
in this neutralizing epitope (N to K and T to E/G).
In V3, mutations occurred almost exclusively within
previously described neutralizing epitopes [26], and at
residues 18, 19 and 27 that have been associated with R5
and X4 tropism [36-38]. One amino acid insertion oc-
curred in the same position in both children and in-
volved a hydrophobic residue (V in child 1; I in child 2).
This type of insertion has also been associated to R5-to-
X4 tropism switch [36,37].
Env adaptation to Nab pressure is usually associated
with positive selection of specific amino acids that might
be located in neutralizing domains [39]. At year 5 of in-
fection there were 10 positively selected sites in Env of
child 1 (seven in gp125) (Table 4). Most sites (6 out of
10) were located in confirmed neutralizing domains (V2,
V3 and C5 in gp125 and MPER in gp36) [27]. In con-
trast, positively selected sites were absent in child 2 at
year 5 of infection and there were only 2 selected sitesgene and C2V3C3 region
diversityb (SD) Evolutionary ratec (95% HPD)
C2-V3-C3 env C2V3C3
0.014 (0.0063) 0.0141 (0.0075, 0.0211) 0.0142 (0.0082, 0.0208)
0.015 (0.0074)
0.031 (0.0118)
0.003 (0.0026) 0.0073 (0.0036, 0.0115) 0.0105 (0.0053, 0.0174)
0.005 (0.0026)
0.055 (0.0157)
c distances and standard deviation (SD) as determined by averaging pairwise
cNucleotide substitutions per site per year (HPD, highest posterior density).
Table 3 Evolution of amino acid diversity in variable Env
regions in the first five years of infection
Patient Variable
regions
Sum of entropy Fold
increaseyear of birth year 5
child 1 V1 1.324 8.657 6.5
V2 0 1.885 na
V3 0.754 3.614 4.8
V4 0.939 0.662 na
V5 0 3.402 na
V1-V5 3.017 18.22 6.0
child 2 V1 0.377 0.754 2.0
V2 1.131 0.377 na
V3 0.377 1.131 3.0
V4 0 1.316 na
V5 0.377 0 na
V1-V5 2.262 3.578 1.6
na- not applicable.
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better adaptation to Nab pressure in child 1 compared
to child 2.
In all, these results show that HIV-2 env can evolve
and diversify very rapidly in the first years of infection.
The positive correlation between the rate of Env evolu-
tion, in terms of nucleotide divergence from the initial
virus, nucleotide diversity, amino acid diversity, and
positive selection, and the rate of Nab response and es-
cape indicates that Nabs likely have a major impact on
HIV-2 Env evolution in the first years of infection.
Tropism and susceptibility to antibody neutralization are
closely associated with V3 structure
In long-term HIV-2 infected individuals the envelope V3
region adopts a significantly different structure in Nab-
resistant isolates as compared to Nab-sensitive isolates,
supporting a direct role of V3 conformation in the
different susceptibility of these viruses to antibody
neutralization [23]. To gain some insight into the struc-
tural evolution of the V3 region in the first years of
HIV-2 infection and try to relate it to tropism and sus-
ceptibility to antibody neutralization, model structures
of C2-V3-C3 regions from both children were generated
by homology modelling using the three-dimensional
structure of an unliganded SIV gp120 envelope glycopro-
tein as template. Remarkably, the V3 loop, which was
characterized by a high content of irregular secondary
structure in the first year of infection, converged to an
similar β-hairpin structure at year five of infection in
both infants and remained in this conformation until the
last year of infection in child 2 (Figure 5 and Additional
file 1: Table S1). The rate of acquisition of the β-hairpin
conformation fully correlated with the rate of R5-to-X4tropism transition and with the rate of escape from anti-
body neutralization.
Discussion
There is limited knowledge on the natural history of
HIV-2 infection and on the molecular and phenotypic
evolutionary dynamics of HIV-2 because no study
has investigated the full course of infection from the
time of seroconversion. The current study is the first
characterization of the Nab response and molecular and
phenotypic evolution of HIV-2 followed from acute in-
fection to late stage infection. Our studies were based on
two children infected by vertical transmission and
spanned the first 12 years of infection in one case and
the complete infection period in the other (9 years). We
show that a potent Nab response is raised very early
after infection and that the rate and pattern of molecular
and phenotypic evolution of the HIV-2 Env are closely
associated to the rate of Nab escape.
Child 2 was born severely ill despite the normal CD4+
T cell percentage [31,32] whereas child 1 was born
asymptomatic and with normal CD4 levels. Despite the
contrasting clinical conditions at birth, major CD4 de-
pletion and disease progression occurred in both chil-
dren in the first 5 years of infection. This fast disease
course is typical of HIV-1 infected children in the ab-
sence of antiretroviral treatment [40] but is highly un-
usual in HIV-2 infected individuals [10,34,41,42]. Both
patients were infected with R5 strains but transitions to
X4 tropism occurred rapidly, being detected after only
5 years of infection. This is the first time that a full R5-
to-X4 tropism switch is observed in HIV-2 infected pa-
tients and it was unexpected to find it in paediatric pa-
tients. Like in some adult HIV-2 patients with advanced
disease [23,37,43], the emergence of X4 viruses in our
patients was associated with high viral load, marked
CD4 depletion and disease progression. Hence, the rapid
disease course in the two infants may have been deter-
mined by the early emergence of X4 isolates.
At birth, HIV-2 nucleotide diversity in child 1 was 2-
fold higher than in child 2 both in env and C2V3C3. Nu-
cleotide diversity in child 1 was also 2-fold higher than
in HIV-1 infected children in the first weeks after birth
[44-46] and in HIV-1 adult patients during seroconver-
sion [47]. Envelope diversity also increased more signifi-
cantly, both at the nucleotide and amino acid levels, in
child 1 than in child 2 in the first 5 years of infection.
Consistently, the evolutionary rate of the env gene in
child 1 was almost two times higher than child 2 and
similar to that found in chronic HIV-2 infected patients
under ART (0.0102 substitutions/site/year) [24]. These
results reveal a remarkably high rate of molecular evolu-
tion of the HIV-2 envelope in child 1 during the first
5 years of infection and a moderate rate of evolution in
Figure 4 Evolution of V1 and V3 regions. Clonal V1 and V3 amino acid sequences obtained over the course of infection from child 1
(panel A) and child 2 (panel B) were aligned against consensus sequences from the initial infecting isolate. Dots in the alignments indicate
sequence identity to the consensus; dashes indicate deletions. Potential N-linked glycans (occurring at NXT/S) are represented in open boxes.
Amino acids highlighted in light grey are involved in tropism change [36]. Blue boxes in the consensus sequence represent published linear
neutralizing epitopes in V1 [28] and V3 [26]; red boxes in the consensus sequence represent a conformational epitope in V3 [26]. Viral tropism is
indicated at the right of the alignment as determined phenotypically or genotypically based on V3 loop sequence patterns. Black arrows signal
fixed mutations.
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Table 4 Positive selective pressure on the Env glycoproteins in both children over the course of infection
Env
glycoprotein
Codons under selective pressure (location)1
Child 1 Child 2
Year of birth Year 2 Year 5 Year of birth Year 5 Year 9
gp125 none 5, 7 (in SP) 178 (V2), 255, 259 (C2), 320 (V3), 459 (V5), 467, 471 (C5) none none 395 (C3)
gp36 none none 552 (HR1), 672, 673 (MPER) none none 562 (HR1)
1Codons identified as being significantly (P <0.05) under selective pressure are indicated; SP, signal peptide; V2, variable region 2; C2, conserved region 2; C3,
conserved region 3; V3, variable region 3; V5, variable region 5; C5, conserved region 5; HR1, helical region 1; MPER, membrane proximal external region.
Rocha et al. Retrovirology 2013, 10:110 Page 9 of 14
http://www.retrovirology.com/content/10/1/110child 2. The evolutionary rate in child 2 was similar to
that in HIV-1 patients who, when untreated, have a dis-
ease progression generally similar to that of child 2.
Thus, the higher rate in child 1 is consistent with the
better immune control.
Previously, we have shown that production of gp36-
specific and gp125-specific antibodies occurred during
the first year of age in child 1 and that, at age 2, levels of
binding antibodies to these glycoproteins were already
similar to those found in HIV-2 infected patients in the
chronic stage of disease [16]. In child 2, although gp36-
specific antibodies were produced to near normal levels,
there was a remarkably weak production of gp125-
specific binding antibodies. Consistently, in this work we
found that child 1 produced a much stronger Nab re-
sponse than child 2. In child 1 autologous neutralizing
antibodies appeared within the first year of infection, in-
creased over time to levels that were similar to chronic-
ally infected patients [18,19,21], and were sustained until
at least the age of 12. Moreover, child 1 also produced a
potent Nab response against several heterologous virus
isolates. As for child 2, the autologous Nab titer was
significantly lower compared to child 1 at age 5 and de-
creased continuously to very low titers following the
rapid decline of CD4 cells and progression to AIDS and
death at age 9. Similar findings have been reported in
late stage disease adult patients in whom Nab titers
decrease in direct association with CD4+ T cell depletion
[23]. Overall, these results suggest that a potent Nab re-
sponse during the acute/early phase of infection might
contribute to control HIV-2 disease progression. Further
investigation of the relationship between Nab response
and disease progression in the acute and early stages of
HIV-2 infection of adult patients is required as this
might provide new insights into the benign course of
most HIV-2 infections.
The differences in Nab response between the two chil-
dren also correlate well with the magnitude and rate of en-
velope evolution in the infants which suggest a close
association between the neutralizing antibody response
and the evolution of the HIV-2 envelope in these patients.
Several lines of evidence further suggest that escape from
Nab response is a major determinant of the evolution
of the HIV-2 envelope in these infants, especially inchild 1. First, complete replacement of virus quasispecies
was noted in phylogenetic analysis of env sequences pro-
duced at the different time points which is compatible
with a situation of ongoing viral escape from antibody
neutralization [48]. Second, amino acid diversity increased
significantly with infection time, especially in V1 and V3
which are major neutralizing domains in HIV-2. This is a
major HIV escape mechanism as a single polymorphism
can alter epitope sequence and/or conformation and
reduce recognition and/or binding affinity by neutralizing
antibodies [39,48-52]. Third, increase in dN/dS ratio and
positive selection in the envelope were closely related to
rate of Nab escape in child 1 [39,51]. Finally, the similar
gain of secondary structure in V3 in both patients
fully correlated with the rate of escape from antibody
neutralization. This has been recently associated to HIV-2
resistance to antibody neutralization in chronic HIV-2 in-
fected patients [23].
Nabs were significantly more potent against R5 isolates
than against X4 isolates (autologous and heterologous)
confirming the inherent resistance of X4 viruses to anti-
body neutralization [23,53]. More importantly, increase in
Nab resistance in child 1 preceded the emergence of X4
variant suggesting that tropism switch may have been
driven by the neutralizing antibodies. Given the immuno-
dominance of the V3 region in HIV-2 infected patients
[54], the location of two of the three amino acid residues
that are associated to R5 and X4 tropism (positions 18
and 19) [36-38] within the first neutralizing epitope in V3
[26] and the major difference in V3 conformation of R5
and X4 strains [23], the close association between HIV-2
susceptibility to antibody neutralization and tropism seen
in these infants is not surprising.
The main limitations of this study are the small num-
ber of patients and the inexistence of viral isolates from
all time points in both children. However, worldwide it
has been impossible to find individuals acutely infected
with HIV-2. Moreover, due to the low or absent viral
load it is often impossible to isolate virus from HIV-2 in-
fected patients. Notwithstanding these limitations, we
believe that our results are a major contribution to our
understanding of the natural history of HIV-2 infection
and of the role of the immune system in controlling and
shaping HIV-2 evolution.
Figure 5 Evolution of the structure of C2-V3-C3 envelope
region. Three-dimensional structures of C2-V3-C3 amino acid
sequences from child 1 and 2 were generated by homology modelling
using the three-dimensional structure of an unliganded SIV gp120
envelope glycoprotein as template. A) Superimposition of the structures
of C2-V3-C3 of child 1 in 1998 (yellow), 2000 (blue) and 2003 (pale red);
B) Superimposition of the structures of C2-V3-C3 of child 2 in 1992
(yellow), 1997 (blue) and 2001 (pale red). V3 loop and C2 and C3
stretches are indicated in the figures. C) Three-dimensional structures of
C2-V3-C3 from child 1 (CT) in 2003 (blue) and child 2 (SC) in1997 (red).
At this time both viruses were X4 and showed resistance to Nabs.
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In conclusion, we show that a potent Nab response is
elicited very early after HIV-2 infection and that the
HIV-2 envelope evolves at a high rate in the first years
of infection, this rate being directly correlated to the po-
tency of the Nab response. R5-to-X4 tropism switch, in-
creased nucleotide and amino acid diversity in V1 and
V3, and convergence of V3 to a β-hairpin structure were
closely associated with escape from the Nab response
suggesting that Nabs have a major impact on the rapid
molecular and phenotypic evolution of the viral envelope
in acute and early in HIV-2 infection. Our studies pro-
vide further support to a model of HIV-2 pathogenesis
in which Nabs play a central role.
Methods
Study subjects and ethics
Two children infected by vertical transmission were stud-
ied. Blood samples were collected from child 1 (patient
PT.HDE.CT), 39 days after birth in 1998, in 1999, 2000,
2001, 2003, 2006 and 2010, and from child 2 (patient PT.
HDE.SC), 27 days after birth in 1992, in 1997 and 2001.
Clinical and immunological characteristics of the patients
are shown in Table 1. Child 1 started ART (stavudine +
lamivudine + lopinavir/ritonavir) in November 2003. Pres-
ently, the child is taking lamivudine + abacavir + lopinavir/
ritonavir; his viral load is undetectable and he is clinically
and immunologically stable. Child 2 started ART with
zidovudine immediately after birth and lamivudine was
added in 2001. In 2001, viral load increased slightly and
CD4+ T cells decreased sharply leading to the child’s
death. Ethical approval was obtained from the Ethics
Committee of Hospital Curry Cabral and written informed
consent was obtained from the children's parents before
entry into the study.
HIV-2 env gene PCR amplification, cloning and
sequencing
Chromossomal DNA was extracted from infected PBMC’s
using Wizard Genomic DNA Purification Kit (Promega)
according to the manufacturer recommendations. A
2600 bp fragment encompassing the entire env gene was
amplified by nested Polymerase Chain Reaction (PCR)
using the Expand Long Template PCR Systemkit (Roche)
and newly designed primers (Additional file 2: Table S2).
The PCR protocol consisted of denaturation at 95°C for
5 min, 35 amplification cycles of 15 sec at 94°C, 30 sec at
59°C and 3 min at 68°C with 5 sec increments and a final
elongation step at 68°C for 30 min. 5 μl of PCR product
was used as the template for nested PCR. The amplifica-
tion profile of the nested PCR was identical to the first
PCR, except for annealing temperature and extension time
(61°C and 2 min respectively). PCR amplicons were
purified with a JETQUICK Gel Extraction Spin Kit
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into the pcDNA3.1/V5-His-TOPO vector (Invitrogen),
using the TOPO TA Expression Kit (Invitrogen) according
to the manufacturer’s instructions. At least eight clones
from each patient/year were sequenced using the BigDye
Terminator V3.1 Cycle sequencing Kit (Applied Biosys-
tems); sequencing primers are displayed in Additional
file 2: Table S2. Sequencing was performed on an ABI
3100–Avant Genetic Analyzer (Applied Biosystems).
Sequence analysis
Clustal × 2.1 [55] software was used to construct align-
ments of HIV-2 env sequences. Reference HIV-2 se-
quences were obtained from the Los Alamos National
Laboratory HIV sequence database [56]. Maximum like-
lihood phylogenetic analyses were performed using the
best-fit model of molecular evolution estimated in PAUP
by Modeltest using likelihood ratio tests [57]. The
chosen model was GTR + I + G. Tree searches were
conducted in PAUP using nearest-neighbour inter-
change (NNI) and tree-bisection plus reconnection
(TBR) heuristic search strategies [58], and bootstrap re-
sampling with 1000 replicates [59]. The genetic dis-
tances between sequences were calculated by averaging
pairwise tree distances using all sequences obtained for
each patient at each time point, as previously described
[60]. Putative recombinants were identified using the
Phi-statistic [61] available in SplitsTree version 4.10
[62] by performing 10 randomized reductions of puta-
tive recombinants. Putative recombinant sequences
were removed before doing the evolutionary rate ana-
lyses. These were: 00PTHDECT_9, 00PTHDECT_16,
00PTHDECT_22, 00PTHDECT_6, 00PTHDECT_24,
00PTHDECT_19, 00PTHDECT_8, 00PTHDECT_12,
03PTHDECT_17, 03PTHDECT_33, 03PTHDECT_21,
01PTHDESC_13, 01PTHDESC_6 and 01PTHDESC_14.
Selective pressure on the HIV-2 Env was examined
with the DATAMONKEY web-server [63], after remov-
ing all positions containing gaps and missing data from
the dataset. All estimations were performed using the
MG94 codon substitution model [64] crossed with the
nucleotide substitution model GTR, previously selected
with Modeltest (see above). The single-likelihood ances-
tor counting (SLAC) method was used to infer the ratio
of nonsynonymous to synonymous nucleotide substitu-
tions (dN/dS) averaged over all codon positions of the
alignment. To identify individual codons under selective
pressure, site-specific dN/dS rates were estimated by the
relaxed-effects likelihood (REL) method, with a cut-off
value for the Bayes factor of 50 [65].
The Bayesian program BEAST was used to estimate
the nucleotide evolutionary rates [66]. The SRD06 model
[67] of substitution was used and two different clock
models were used, relaxed lognormal and strict clock. Aconstant parametric demographic model as well as the
non-parametric Skyline plot with 3 groups was tested. The
MCMC chains were chosen so that the effective sample
size for all parameters exceeded 300 and convergence
was assessed by inspecting the traces in the program
Tracer [68]. Appropriate demographic and molecular
clock models were chosen by examining the marginal pos-
terior distributions of relevant parameters.
Potential N-linked glycosylation sites were identified
using the N-Glycosite software [69] and the entropy at
each position in protein alignment was measured with
Shannon’s entropy [70], both available at the Los Alamos
National Laboratory HIV sequence database [56].
Virus isolation and tropism characterization
Primary virus isolates were obtained from both patients
using the co-cultivation method as described previously
[32]. Viral tropism (CCR5 and/or CXCR4 usage) was de-
termined in TZM-bl cells in the presence of CCR5 or
CXCR4 antagonists as described previously [22]. Trop-
ism was also determined genetically using the V3 loop
clonal sequences and the algorithm described by Vis-
seuxet al [36] which is based in the sequence, size and
charge of the V3 loop.
Neutralization assay
The neutralizing activity present in patients serum was
analyzed against autologous and heterologous primary
virus isolates using a luciferase reporter gene assay in
TZM-bl cells, as described previously [2,53,71]. Briefly,
the cells [10,000 cells in 100 μl of complete growth
medium (GM) that consists of DMEM supplemented
with 10% heat-inactivated fetal bovine serum (FBS)],
were added to each well of 96-well flat-bottom culture
plates (Nunc) and allowed to adhere overnight. One
hundred μl of each virus (corresponding to 200 TCID50)
were incubated for 1 h at 37°C with 2-fold serial dilu-
tions of heat-inactivated patients sera in a total volume
of 200 μl of GM containing DEAE-Dextran (20 μg/ml).
The lowest serum dilution used in the assays was 1:80.
Forty-eight hours later, plates were analyzed for lucifer-
ase activity on a luminometer (TECAN) using the One-
Glow Luciferase Assay System (Promega, Madison, WI).
Medium only control wells were measured as back-
ground, and virus-only control wells were included as
100% infection. Neutralization titers were expressed as
the reciprocal of the plasma dilution that inhibited virus
infection by 50% (IC50). IC50 was estimated by the sig-
moidal dose–response (variable slope) equation in Prism
version 5.0 [72]. Nonspecific inhibition was assessed by
testing all HIV-2 isolates against HIV-negative plasma
and all plasma samples against HIV-1 strain SG3.1 and
HIV-1 SG3.1 pseudotyped with VSV envelope (using
pSG3Δenv as backbone).
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Structural models of the C2-V3-C3 domain in gp125 were
produced with SWISS-MODEL homology modelling ser-
ver in automated mode, using PDB file 2BF1 (SIV) as tem-
plate [73,74]. Accelrys Discovery Studio 2.1 (Accelrys Inc.,
San Diego, USA, 2008) was used to produce three dimen-
sional images of the obtained models and perform the sec-
ondary structure analysis of the V3 loop.
Statistical analysis
Statistical analysis was performed with GraphPad Prism
5.0 [72] with a level of significance of 5%. F test was used
to compare best fit values of IC50 slopes obtained with
CT00 and CT03 isolates from child 1. Non parametric
Mann Whitney test was used to compare autologous
Nab responses (mean IC50s) between child 1 and child
2. To compare evolutionary rates we computed the pos-
terior probability (PP) that one rate exceeded the other
and the probability was determined numerically by ran-
domly sampling from the empirical posterior distribu-
tions [24]. Kruskal-Wallis test was used to compare
mean Shannon’s entropies between variable Env regions
of both patients.
GenBank accession numbers
Full-length envelope sequences generated in this study
are available from GenBank under the following acces-
sion numbers: GU983917-GU983940 and JX219591-
JX219614.
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and 2.
Additional file 2: Table S2. PCR and sequencing primers for the HIV-2
env gene. aOuter PCR primer; bInner PCR primer; cSequencing primer.
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